The evolving treatment paradigm of lung cancer in China

Acta Pharm Sin B. 2022 Mar;12(3):1536-1537. doi: 10.1016/j.apsb.2022.01.010. Epub 2022 Jan 29.

¹ Pharmcube (Beijing) Co., Ltd., Beijing 100020, China.
² National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
³ Tsinghua Clinical Research Institute (TCRI), School of Medicine, Tsinghua University, Beijing 100089, China.

No abstract available